



Date: November 20, 2008

To: Jennifer Vermeer, Director
Iowa Medicaid Enterprise

Senator Schmitz

Senator Kreiman

Senator Seymour

Representative Wenthe

Representative Heddens

Representative Upmeyer

From: Thomas R. Temple, R.PH., M.S., CEO & Executive Vice President

Iowa Pharmacy Association

RE: Legislative Interim Committee on Medicaid Drug Product Selection

In response to the Legislative Interim Committee on Medicaid Drug Product Selection, IPA submits the following recommendations to Iowa Department of Human Services and the Legislative Interim Committee for its consideration:

1. Resist change to Iowa's Drug Product Selection Law.
2. Preclude the inclusion of brand name drugs on the PDL where there exists a generic equivalent for such drugs.
3. Explore ways of increasing transparency in the PDL process, both as it relates to administrative and financial activity.
4. Separate contract vendors for the DUR and P&T processes.
5. Expand MTM and implement chronic care disease management programs within the Medicaid program.

Advancing patient health through communication, education and innovation.

8515 Douglas, Suite 16 • Des Moines, IA 50322 • 515/270-0713 • FAX 515/270-2979

Website: www.iarx.org • E-mail: IPA@iarx.org